Aktis Oncology(AKTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AKTS Aktis Oncology

Trading 05-22 12:28:53 EDT

19.78

+0.66

+3.45%

High20.10	Low19.20	Vol39.97K
Open19.46	D1 Closing19.12	Amplitude4.71%
Mkt Cap1.09B	Tradable Cap349.12M	Total Shares55.28M
T/O781.28K	T/O Rate0.23%	Tradable Shares17.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AKTS","market":"US","secType":"STK","nameCN":"Aktis Oncology","latestPrice":19.78,"timestamp":1779467329007,"preClose":19.12,"halted":0,"volume":39968,"delay":0,"changeRate":0.03451882845188285,"floatShares":17650000,"shares":55276000,"eps":-1.213,"marketStatus":"Trading","change":0.66,"latestTime":"05-22 12:28:53 EDT","open":19.46,"high":20.1,"low":19.2,"amount":781284.07232,"amplitude":0.047071,"askPrice":19.89,"askSize":105,"bidPrice":19.69,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.213,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779480000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1767934800000,"exchange":"NASDAQ","adjPreClose":19.12,"postHourTrading":{"tag":"盘后","latestPrice":19.12,"preClose":19.12,"latestTime":"19:59 EDT","volume":1512,"amount":28878.99,"timestamp":1779407981092,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.569226,"impliedVol":1.5345,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AKTS","defaultTab":"news","newsList":[{"id":"2637631645","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2637631645","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637631645?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:18","pubTimestamp":1779448694,"startTime":"0","endTime":"0","summary":"PicoCELA  shares were up 172% in Friday premarket activity, extending Thursday's 60% rally.Leifras  stock was 113% higher after the company agreed to acquire Tokai Sports.Akari Therapeutics  shares were up 64% after the company reported positive preclinical data for its AKTX-101 investigational drug candidate.MetaVia  stock was 40% higher following a muted session.HCW Biologics  shares were up 25% after the company priced a private securities offering.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4204","BK4139","BK4148","LFS","AKTX","BK7093","PCLA","AKTS","BK4539","HCWB","BK4007","BK4020","MTVA","LFS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637949783","title":"Aktis Oncology (AKTS) Valuation Check After Recent Share Price Weakness And Lower Price To Book Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2637949783","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637949783?lang=en_us&edition=fundamental","pubTime":"2026-05-22 15:38","pubTimestamp":1779435488,"startTime":"0","endTime":"0","summary":"Aktis Oncology stock: key recent moves\nAktis Oncology (AKTS) has drawn attention after recent trading left the stock at a last close of $19.12, with short term returns mixed and year to date performance currently showing a double digit decline.\nSee our latest analysis for Aktis Oncology.\nRecent trading shows momentum fading, with a 7 day share price return of 1.95% lower and a 30 day share price return of 6.73% lower, while the year to date share price return is 14.64% lower from the current...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akts/aktis-oncology/news/aktis-oncology-akts-valuation-check-after-recent-share-price","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akts/aktis-oncology/news/aktis-oncology-akts-valuation-check-after-recent-share-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AKTS","BK4148","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357765","title":"Aktis Oncology reports first-in-human AKY-2519 imaging data showing robust tumor uptake","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357765","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357765?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:39","pubTimestamp":1779399551,"startTime":"0","endTime":"0","summary":"Aktis Oncology released first-in-human imaging and dosimetry findings for its B7-H3-targeted radioconjugate AKY-2519, with data scheduled for presentation at the 2026 ASCO Annual Meeting on May 30.The readout showed strong tumor uptake with limited exposure in normal tissues across assessments in metastatic castration-resistant prostate cancer and a broader set of advanced solid tumors.The profile supported continued clinical development, including an ongoing Phase 1b study in mCRPC that includes PLUVICTO-nave and PLUVICTO-experienced patients, with preliminary data expected in 2027.A second Phase 1b study in other B7-H3-expressing solid tumors is planned to start in the second half of 2026, expanding the program beyond prostate cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL1ycsH3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKTS","BK4148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637977357","title":"Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for Aky-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients With B7-H3 Expressing Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2637977357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637977357?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:21","pubTimestamp":1779398468,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA8QPGQZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4148","AKTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634255803","title":"Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634255803","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634255803?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:50","pubTimestamp":1778536214,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX) ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aktis-oncology-inc-akts-metagenomi-inc-mgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aktis-oncology-inc-akts-metagenomi-inc-mgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKTS","MGX","BK4588","BK4137","BLSG","BLSX","LABU","BK4112","LU0128526141.USD","XBI","BK4581","BK4148","BK4585","BK4139","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634253271","title":"Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M","url":"https://stock-news.laohu8.com/highlight/detail?id=2634253271","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634253271?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:36","pubTimestamp":1778535418,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents and marketable securities were $538.5M as of March 31, compared to $226.8M as of December 31, 2025. “We continue to build mo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aktis-oncology-reports-q1-revenue-3-23m-consensus-1-85m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aktis-oncology-reports-q1-revenue-3-23m-consensus-1-85m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634253459","title":"Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634253459","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634253459?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:35","pubTimestamp":1778535353,"startTime":"0","endTime":"0","summary":"Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.64 percent. This is a 97.96 percent increase over losses of $(18.60) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52472867/aktis-oncology-q1-eps-0-38-beats-0-44-estimate-sales-3-227m-beat-1-750m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232223","title":"Aktis Oncology Q1 FY26 net loss widens to $18.3 million; revenue climbs to $3.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232223","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232223?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:06","pubTimestamp":1778529974,"startTime":"0","endTime":"0","summary":"Aktis Oncology posted a net loss of $18.3 million for first-quarter 2026, widening from a $15 million loss a year earlier.Collaboration revenue rose to $3.2 million from $1.4 million, on continued advancement of its research collaboration with Eli Lilly.R&D expenses climbed to $20 million from $15.9 million, while G&A costs increased to $5.9 million from $3.7 million.Cash, cash equivalents and marketable securities totaled $538.5 million at March 31, up from $226.8 million at year-end 2025, following gross IPO proceeds of about $365.4 million; cash runway expected into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data G","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLqKvZg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELIS","LU0106261372.USD","LU2089984988.USD","LU0109391861.USD","LU2168564222.USD","LU0943347566.SGD","LU1623119135.USD","SG9999014914.USD","BK4139","LU0114720955.EUR","LU0238689110.USD","LU0289739699.SGD","LU2461242641.AUD","LU1629891620.HKD","LU0316494557.USD","IE00BFTCPJ56.SGD","LU1868837300.USD","IE00BN29S564.USD","LU2028103732.USD","LU2168563687.JPY","LU0234572021.USD","IE0004445015.USD","IE00B2B36J28.USD","IE00B1XK9C88.USD","LU2360106947.USD","BK4585","LU1548497426.USD","LU2552382058.USD","SG9999018857.SGD","LU0823416689.USD","LU2111349929.HKD","LLYX","LU1145028129.USD","LU1720051108.HKD","LU1280957306.USD","LU1127390331.HKD","LU2023250504.SGD","LU0353189763.USD","LU2237443622.USD","LU0353189680.USD","LU2168564495.EUR","IE00B4JS1V06.HKD","IE00B4R5TH58.HKD","LU2237443978.SGD","LU0471298694.HKD","BK4534","LU0683600562.USD","LU1023059063.AUD","LU2106854487.HKD","SG9999001176.SGD","LU2756315664.SGD","LU2456880835.USD","IE00BJLML261.HKD","IE00B775H168.HKD","LU1988902786.USD","LU1551013342.USD","LU0786609619.USD","LU1267930730.SGD","LU1551013425.SGD","LU1868837136.USD","LU2361044949.HKD","LU2271345857.HKD","LU0079474960.USD","LU0820562030.AUD","LU0198837287.USD","IE00BK4W5L77.USD","LU0889565916.HKD","LU1064131342.USD","BK4581","LU1069344957.HKD","LU1868836914.USD","LU2750360641.GBP","SG9999015945.SGD","LU2417539215.USD","LU0708995401.HKD","LU2552382215.SGD","IE00BFSS7M15.SGD","LU0417517546.SGD","LU0820561909.HKD","LU2361044865.SGD","LU0466842654.USD","LU2491049909.HKD","LU2756315318.SGD","LU0122379950.USD","BK4148","SG9999018865.SGD","LU2237438978.USD","LU2237443549.SGD","LU2471134952.CNY","IE0004445239.USD","SGXZ57979304.SGD","ELIL","LU1366192091.USD","SG9999015952.SGD","LU0256863902.USD","IE0009355771.USD","IE00BJJMRY28.SGD","LU1093756168.USD","SGXZ99366536.SGD","LLII","LU1868836591.USD","SG9999014898.SGD","LU2023251221.USD","LU1868836757.USD","LU0323591593.USD","LU0203202063.USD","LU1989771016.USD","IE00BJT1NW94.SGD","LU0006306889.USD","SGXZ31699556.SGD","LU0097036916.USD","IE00BJJMRZ35.SGD","IE00BKDWB100.SGD","LU0158827781.USD","LU2236285917.USD","LU0689472784.USD","AKTS","BK4599","IE0002141913.USD","LU2063271972.USD","LU2746668974.SGD","LU0158827948.USD","LU2264538146.SGD","LU1093756325.SGD","LU0133085943.USD","SG9999013999.USD","SG9999014880.SGD","LU2471134523.USD","LU0210536198.USD","LU0266013472.USD","LU2237443465.HKD","LU1712237335.SGD","LU0820561818.USD","LU1232071149.USD","LU2265009873.SGD","LU0058720904.USD","LU2357305700.SGD","LU2089283258.USD","LU0432979614.USD","LU2108987350.USD","IE00BK4W5M84.HKD","LU1814569148.SGD","SGXZ51526630.SGD","LU0354030438.USD","LU0456855351.SGD","SG9999014906.USD","LU0882574139.USD","LU1061106388.HKD","LU2896262040.SGD","LU2168564065.EUR","LU1291159041.SGD","LU0471298777.SGD","LU2324357040.USD","LU0320765059.SGD","LU2746668461.USD","SG9999015986.USD","LU1035775433.USD","LU1057294990.SGD","LU2361045086.USD","LU0320765992.SGD","SGXZ81514606.USD","IE0001KFT4U8.USD","IE00BKPKM429.USD","LU0096364046.USD","LU1983299246.USD","LU2089284900.SGD","GB00BDT5M118.USD","LU1804176565.USD","LU0640476718.USD","LU2112291526.USD","LU2168564149.EUR","SG9999001176.USD","BK4007","LU0256863811.USD","LU2462157665.USD","LU0787776722.HKD","LU0109394709.USD","LU2471134796.USD","SG9999017495.SGD","IE00B1BXHZ80.USD","LU0385154629.USD","LU0354030511.USD","LU1720051017.SGD","LU2211815571.USD","BK4533","LU0061475181.USD","LU2491050154.USD","LU0094547139.USD","LU2237443382.USD","LU2602419157.SGD","BK4516","LU2468319806.SGD","SG9999015978.USD","LU0225283273.USD","LU0823434740.USD","LU2750360997.AUD","LLYZ","LU0882574055.USD","IE00BFSS8Q28.SGD","LU2471134879.HKD","IE00BJJMRX11.SGD","LU2213496289.HKD","LU1917777945.USD","LU0203201768.USD","LU0672654240.SGD","BK4588","LU1974910355.USD","LU2237443895.HKD","LU0823434583.USD","LU1323610961.USD","LU2491050071.SGD","LU2552382132.HKD","LU0964807845.USD","LU2087625088.SGD","IE0005OL40V9.USD","LU2023250330.USD","IE00B7KXQ091.USD","IE00BWXC8680.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232655","title":"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232655","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232655?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529660,"startTime":"0","endTime":"0","summary":"Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segmentsInitiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3292282/0/en/Aktis-Oncology-Reports-Financial-Results-and-Business-Highlights-for-First-Quarter-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTS","BK4148","IND","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633336831","title":"Aktis Oncology to Present at the BofA Securities Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633336831","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633336831?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068800,"startTime":"0","endTime":"0","summary":"BOSTON, May  06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmac","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288736/0/en/Aktis-Oncology-to-Present-at-the-BofA-Securities-Health-Care-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4139","BK4588","BK4585","LABU","XLV","BK4148","XBI","AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633942857","title":"Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and mCRPC Opportunity for AKY‑2519","url":"https://stock-news.laohu8.com/highlight/detail?id=2633942857","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633942857?lang=en_us&edition=fundamental","pubTime":"2026-05-05 23:45","pubTimestamp":1777995922,"startTime":"0","endTime":"0","summary":"William Blair analyst Alexandra Ramsey has reiterated their bullish stance on AKTS stock, giving a Buy rating on April 21. Alexandra Ramsey has giv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aktis-oncology-initiated-at-buy-on-differentiated-radiopharmaceutical-platform-and-mcrpc-opportunity-for-aky‑2519-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aktis-oncology-initiated-at-buy-on-differentiated-radiopharmaceutical-platform-and-mcrpc-opportunity-for-aky‑2519-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4148","AKTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633483910","title":"Aktis Oncology posts presentation outlining AKY-2519 Phase 1b clinical development strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2633483910","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633483910?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:08","pubTimestamp":1777982909,"startTime":"0","endTime":"0","summary":"Aktis outlined a two-trial Phase 1b plan for AKY-2519, a B7-H3-targeted miniprotein radioconjugate, starting with a dedicated metastatic castration-resistant prostate cancer study.mCRPC Phase 1b has been initiated, with dose escalation using a BOIN design and expansion cohorts planned for PLUVICTO-naive patients plus PLUVICTO-experienced patients.Entry requires tumor uptake on imaging with [64Cu]Cu-AKY-2519, positioning trial to compare B7-H3 expression with PSMA expression.Imaging and dosimetry datasets are slated for presentation at ASCO 2026, with preliminary mCRPC Phase 1b data expected in 2027.Basket Phase 1b in B7-H3-expressing lung, colorectal, and other solid tumors is expected to start in 2H’26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL9kqQfH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4148","AKTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633896145","title":"Aktis Oncology initiates clinical trial of AKY-25191","url":"https://stock-news.laohu8.com/highlight/detail?id=2633896145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633896145?lang=en_us&edition=fundamental","pubTime":"2026-05-05 05:11","pubTimestamp":1777929108,"startTime":"0","endTime":"0","summary":"Aktis Oncology (AKTS) announced the initiation of a Phase 1b clinical trial of AKY-25191 in patients with metastatic castration-resistant prostate ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aktis-oncology-initiates-clinical-trial-of-aky-25191-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aktis-oncology-initiates-clinical-trial-of-aky-25191-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AKTS","BK4148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633963733","title":"Aktis Oncology Initiates Phase 1B Clinical Trial for Aky-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (Mcrpc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633963733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633963733?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA1X8LHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4148","AKTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631510860","title":"Aktis Oncology Initiated at Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2631510860","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631510860?lang=en_us&edition=fundamental","pubTime":"2026-04-29 21:42","pubTimestamp":1777470120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKTS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 09:42 ET (13:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631518289","title":"William Blair Initiates Aktis Oncology at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2631518289","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631518289?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:14","pubTimestamp":1777461248,"startTime":"0","endTime":"0","summary":"Aktis Oncology, Inc. (AKTS) has an average rating of buy and mean price target of $32.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629063666","title":"Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629063666","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629063666?lang=en_us&edition=fundamental","pubTime":"2026-04-22 05:00","pubTimestamp":1776805200,"startTime":"0","endTime":"0","summary":"AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentationsData facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278532/0/en/Aktis-Oncology-Announces-Presentation-of-First-Clinical-Imaging-and-Dosimetry-Data-for-AKY-2519-at-the-2026-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4148","AKTS","BK4117","AFG","BK4107","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628763734","title":"Aktis Oncology Board Shift And New Committee Draw Investor Focus On R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2628763734","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628763734?lang=en_us&edition=fundamental","pubTime":"2026-04-19 13:03","pubTimestamp":1776575011,"startTime":"0","endTime":"0","summary":"Aktis Oncology (NasdaqGS: AKTS) has appointed Dr. Glenn Gormley as an independent director to its Board.\nDr. Gormley will also serve as co-chair of a newly formed Science and Technology Committee.\nThe company announced upcoming departures of two current Board members as part of this transition.\n\nAktis Oncology, trading on NasdaqGS under the ticker AKTS, recently closed at $20.25. The stock is up 20.0% over the past week and 14.4% over the past 30 days, while the year-to-date return stands at...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akts/aktis-oncology/news/aktis-oncology-board-shift-and-new-committee-draw-investor-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akts/aktis-oncology/news/aktis-oncology-board-shift-and-new-committee-draw-investor-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4148","BK4139","AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628724622","title":"Aktis Oncology director Glenn Gormley files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2628724622","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628724622?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:05","pubTimestamp":1776369958,"startTime":"0","endTime":"0","summary":"Aktis Oncology filed an initial Form 3 for director Glenn Gormley dated April 15, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDLbHbhz7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTS","BK4139","BK4148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627021219","title":"Aktis Oncology appoints Gormley as independent director of Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2627021219","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627021219?lang=en_us&edition=fundamental","pubTime":"2026-04-16 22:16","pubTimestamp":1776348974,"startTime":"0","endTime":"0","summary":"Aktis Oncology (AKTS) announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aktis-oncology-appoints-gormley-as-independent-director-of-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aktis-oncology-appoints-gormley-as-independent-director-of-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKTS","BK4139","BK4148"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aktisoncology.com","stockEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0673},{"period":"3month","weight":0.0116},{"period":"6month","weight":0.0622},{"period":"ytd","weight":0.0622}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.0549},{"period":"3month","weight":0.0773},{"period":"6month","weight":0.127},{"period":"1year","weight":0.2743},{"period":"ytd","weight":0.0892}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells radio frequency (RF) filter products for the wireless industry in the Americas, Asia, Europe, and internationally. It operates in two segments, Fabrication Services and RF Filters. The Fabrication Services segment provides engineering review and backend packaging services. The RF Filters segment sells amplifier and filter products. It offers RF filters for the wireless industry, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company also sells complementary surface acoustic wave resonators, crystal (Xtal) resonators and oscillators, and ceramic products; and provides back-end semiconductor supply chain services. Akoustis Technologies, Inc. is headquartered in Huntersville, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.07242},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.009578},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.089105},{"month":4,"riseRate":0.25,"avgChangeRate":-0.011983},{"month":5,"riseRate":0.5,"avgChangeRate":-0.07198},{"month":6,"riseRate":0.5,"avgChangeRate":-0.041124},{"month":7,"riseRate":0.25,"avgChangeRate":-0.065017},{"month":8,"riseRate":0.5,"avgChangeRate":-0.046698},{"month":9,"riseRate":0.375,"avgChangeRate":-0.092023},{"month":10,"riseRate":0.375,"avgChangeRate":-0.160528},{"month":11,"riseRate":0.625,"avgChangeRate":0.149228},{"month":12,"riseRate":0.375,"avgChangeRate":0.01269}],"exchange":"NASDAQ","name":"Aktis Oncology","nameEN":"Aktis Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aktis Oncology(AKTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aktis Oncology(AKTS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aktis Oncology,AKTS,Aktis Oncology股票,Aktis Oncology股票老虎,Aktis Oncology股票老虎国际,Aktis Oncology行情,Aktis Oncology股票行情,Aktis Oncology股价,Aktis Oncology股市,Aktis Oncology股票价格,Aktis Oncology股票交易,Aktis Oncology股票购买,Aktis Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aktis Oncology(AKTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aktis Oncology(AKTS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction